

ADHD-Phyto: A PhytoIntelligence-Based Nutraceutical Formulation for Attention-Deficit/Hyperactivity Disorder

Generated with PhytoIntelligence Framework v1.1

September 12, 2025

Abstract

This report applies the PhytoIntelligence framework to Attention-Deficit/Hyperactivity Disorder (ADHD). By integrating AI-driven literature mining, molecular docking predictions, pharmacokinetic modeling, bioavailability strategies, synergy analysis, and regulatory compliance, a proposed multi-compound formulation (**ADHD-Phyto**) is presented. This work is strictly theoretical and requires in vitro, in vivo, and clinical testing prior to any clinical application.

1 Observations and Preliminary Analysis

ADHD involves dopaminergic and noradrenergic dysregulation, oxidative stress, impaired neuroplasticity, and mitochondrial dysfunction. Current pharmacological treatments (e.g., methylphenidate, atomoxetine) are effective but carry risks of side effects such as appetite loss, insomnia, and anxiety. Nutraceuticals have shown promise but are typically tested in isolation with mixed efficacy. A systematic, multi-compound approach may address the multifactorial nature of ADHD.

2 Literature Review and Rationale

- **Neurotransmitter Modulation:** L-Theanine, Rhodiola rosea, and Ginkgo biloba enhance dopamine, norepinephrine, and GABA balance.
- **Neuroprotection and Plasticity:** Bacopa monnieri, Curcumin, and EGCG show antioxidant and neurotrophic activity.
- **Mitochondrial Support:** Omega-3 fatty acids and Phosphatidylserine improve neuronal energetics and membrane integrity.
- **Synergy Evidence:** Bacopa + Rhodiola enhance cognition under stress; Curcumin + Piperine improve bioavailability; Omega-3 + Phosphatidylserine act synergistically for membrane fluidity and dopamine signaling.

3 Research Question

Can a multi-compound nutraceutical formulation designed using the PhytoIntelligence framework achieve multi-target efficacy for ADHD while maintaining safety and regulatory compliance?

4 Hypothesis

By integrating adaptogens, polyphenols, amino acid derivatives, and metabolic cofactors, the ADHD-Phyto formulation will demonstrate synergistic improvements in attention, neuroprotection, and behavioral regulation compared to single-compound nutraceuticals.

5 Materials and Methods

We apply the PhytoIntelligence composite model:

$$C_{\text{ADHD}} = \sum_{i=1}^n (M_i \times V_i \times P_i \times B_i \times S_i \times R_i \times D_i)$$

where:

- M_i : Molecule identification factor (literature mining score)
- V_i : Clinical validation score (in vitro, in vivo, clinical evidence)
- P_i : Pharmacokinetics factor (ADME profile)
- B_i : Bioavailability coefficient
- S_i : Synergy factor
- R_i : Regulatory compliance score
- D_i : Dosage safety coefficient

6 Proposed ADHD-Phyto Formulation

Compound	Dose (mg/day)	Mechanism	Notes
Bacopa monnieri (20% bacosides)	300	Enhances memory, synaptic plasticity	Cognitive enhancer
Rhodiola rosea (3% rosavins, 1% salidroside)	200	Dopamine/norepinephrine modulation	Adaptogen

Compound	Dose (mg/day)	Mechanism	Notes
L-Theanine	200	Alpha-wave induction, calm focus	Synergy with stimulants
Omega-3 (EPA 600/DHA 400)	1000	Membrane fluidity, dopamine regulation	Clinical ADHD evidence
Curcumin (95% standardized)	250	Anti-inflammatory, neurotrophic	With Piperine for absorption
Piperine	10	Enhances Curcumin bioavailability	Bioavailability booster
Ginkgo biloba (24% flavone glycosides)	120	Improves cerebral blood flow, executive function	Moderate ADHD evidence
Phosphatidylserine	200	Supports dopamine release, cognition	Synergy with Omega-3

7 Mechanistic Targeting

- **Catecholamine Regulation:** Rhodiola, L-Theanine, Omega-3, Phosphatidylserine
- **Neuroprotection:** Bacopa, Curcumin, Ginkgo, Omega-3
- **Oxidative Stress Reduction:** Curcumin, Ginkgo, Omega-3
- **Cognitive Enhancement:** Bacopa, L-Theanine, Phosphatidylserine
- **Bioavailability Support:** Piperine

8 Discussion

The ADHD-Phyto formulation combines adaptogens, polyphenols, and metabolic cofactors with complementary mechanisms. Predicted synergies include Bacopa–Rhodiola, Curcumin–Piperine, and Omega-3–Phosphatidylserine. Limitations include reliance on fragmented clinical evidence and computational modeling rather than validated clinical trials. Regulatory alignment is strong, as all compounds have Generally Recognized as Safe (GRAS) or EFSA-approved status.

9 Conclusion

ADHD-Phyto represents a theoretically optimized nutraceutical for ADHD, developed through the PhytoIntelligence framework. It is designed to target dopaminergic balance, neuroprotection, oxidative stress, and attention regulation. Experimental validation in preclinical and clinical settings is required before translation to practice.

Regulatory Note

All ingredients are within Generally Recognized as Safe (GRAS) or EFSA-equivalent safety categories. Doses remain below established No Observed Adverse Effect Levels (NOAEL). This report is for research purposes only and does not constitute medical advice.

References

1. Chang J.-P., Su K.-P., Mondelli V., Pariante C.M. (2018). Omega-3 polyunsaturated fatty acids in youths with ADHD: a systematic review and meta-analysis. *Neuropsychopharmacology*, 43(3), 534–545.
2. Händel M.N., Rohde J.F., et al. (2021). PUFA supplementation in ADHD: a systematic review and meta-analysis. *Nutrients*, 13(4):1226.
3. Kean J.D., Downey L.A., Sarris J., et al. (2022). Bacopa monnieri in inattentive and hyperactive boys: RCT. *Phytotherapy Research*.
4. Hirayama S., Terasawa K., et al. (2014). Phosphatidylserine in ADHD: randomized controlled trial. *J Hum Nutr Diet*, 27 Suppl 2, 284–291.
5. Shoba G., Joy D., Joseph T., et al. (1998). Piperine enhances Curcumin bioavailability. *Planta Medica*, 64(4), 353–356.
6. Lyon M.R., Kapoor M.P., Juneja L.R. (2011). L-theanine improves sleep in boys with ADHD. *Alt Med Rev*, 16(4), 348–354.
7. Kahathuduwa C.N., Wakefield S., et al. (2020). L-theanine–caffeine effects on attention in ADHD children. *Scientific Reports*, 10:13072.
8. Salehi B., Imani R., Mohammadi M.R., et al. (2010). Ginkgo biloba in ADHD: double blind RCT. *Prog Neuropsychopharmacol Biol Psychiatry*, 34(1), 76–80.
9. Al Shahab S., Al Balushi R., Qambar A., et al. (2025). Supplements for ADHD symptoms: systematic review. *Nutrients*, 17(9):1482.
10. Landry, M.S. (2025). *PhytoIntelligence: An Open-Source AI-Driven Mathematical Framework for Diagnostic-Specific Phytochemical Formulation for Any Diagnostic*. Open-source white paper.